AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Kymera Therapeutics Inc. (KYMR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

37.48

-0.17 (-0.45%)

At close: Feb 20, 2025, 3:59 PM

37.42

-0.16%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	35
Market Cap	2.43B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.34
PE Ratio (ttm)	-16.02
Forward PE	n/a
Analyst	Buy

Ask	41.25
Volume	361,263
Avg. Volume (20D)	490,867
Open	37.40
Previous Close	37.65
Day's Range	36.70 - 38.05
52-Week Range	29.24 - 53.27
Beta	undefined

About KYMR

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Aug 21, 2020

Employees 184

Stock Exchange NASDAQ

Ticker Symbol KYMR

Website https://www.kymeratx.com

Full Company Profile

Analyst Forecast

According to 15 analyst ratings, the average rating for KYMR stock is "Buy." The 12-month stock price forecast is $56, which is an increase of 49.41% from the latest price.

Buy 80.00%

Hold 20.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Kymera Therapeutics Inc. is scheduled to release its earnings on Feb 27, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+7.61%

Kymera Therapeutics shares are trading higher. Ste... Unlock content with Pro Subscription

1 month ago

+7.79%

Kymera Therapeutics shares are trading higher after the company announced it's targeting 2025 milestones with its STAT6 and TYK2 oral degraded programs for immunology.

News

1 month ago · zacks.com

Kymera Provides Pipeline Objectives for 2025, Stock Gains

KYMR outlines plans to advance its immunology candidates. As of Dec. 31, 2024, KYMR had $850 million in cash that should fund its operations into mid-2027.

1 month ago · zacks.com

Kymera Therapeutics (KYMR) Moves 7.8% Higher: Will This Strength Last?

Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength ...

2 months ago · seekingalpha.com

Kymera: Protein Degradation Could Drive Dupixent-Like Value

Kymera Therapeutics' KT-474, partnered with Sanofi, is in Phase 2 trials for Hidradenitis Suppurativa and Atopic Dermatitis, with completion of studies expected mid-2026. KT-621, a STAT6 degrader for ...